公开(公告)号：EP3204505B1

公开(公告)日：2020-05-06

申请号：EP15788249.9

申请日：2015-10-09

申请人： GenVec, Inc.

发明人： BROUGH, Douglas E. ,  ETTYREDDY, Damodar R.

IPC分类号： C12N15/861 ,  C07K14/47 ,  A61K48/00

公开(公告)号：EP2916862A2

公开(公告)日：2015-09-16

申请号：EP13795397.2

申请日：2013-11-12

申请人： GenVec, Inc.

发明人： CHEN, Ping ,  MCVEY, Duncan ,  BROUGH, Douglas ,  BRUDER, Joseph

IPC分类号： A61K39/015

CPC分类号： A61K39/015 ,  A61K2039/5256 ,  A61K2039/53 ,  Y02A50/412

摘要： The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.

公开(公告)号：EP1951297A2

公开(公告)日：2008-08-06

申请号：EP06846283.7

申请日：2006-11-13

申请人： GenVec, Inc.

发明人： BROUGH, Douglas E. ,  BRUDER, Joseph T. ,  KING, C. Richter

IPC分类号： A61K39/135 ,  C12N15/861

CPC分类号： A61K39/135 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/552 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2770/32134 ,  C12N2770/32171

摘要： The invention is directed to an adenoviral vector comprising at least one nucleic acid sequence encoding an aphthovirus antigen and/or a cytokine operably linked to a promoter. The adenoviral vector is replication-deficient and requires at most complementation of both the E1 region and the E4 region of the adenoviral genome for propagation. The invention also is directed to a method of inducing an immune response in a mammal comprising administering to the mammal a composition comprising the aforementioned adenoviral vector.

公开(公告)号：EP0811069B1

公开(公告)日：2008-05-28

申请号：EP96906417.9

申请日：1996-02-13

申请人： GENVEC, INC. ,  CORNELL RESEARCH FOUNDATION, INC.

发明人： WICKHAM, Thomas, J. ,  FALCK-PEDERSEN, Erik ,  ROELVINK, Petrus, W. ,  BRUDER, Joseph, T. ,  GALL, Jason ,  KOVESDI, Imre

IPC分类号： C12N15/62 ,  C12N15/86 ,  C07K14/075 ,  A61K48/00

CPC分类号： C12N15/86 ,  A61K48/00 ,  C07K14/005 ,  C07K2319/00 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2810/405 ,  C12N2810/6018 ,  C12N2830/00 ,  C12N2830/60

公开(公告)号：EP1137758B1

公开(公告)日：2008-02-27

申请号：EP99966096.2

申请日：1999-12-10

申请人： GENVEC, INC.

发明人： KOVESDI, Imre ,  RANSOM, Stephen, C.

IPC分类号： C12N7/00 ,  C12N15/861 ,  A61K47/26 ,  A61K47/32

CPC分类号： C12N15/86 ,  A61K47/183 ,  A61K47/26 ,  A61K47/32 ,  A61K48/0091 ,  C12N2710/10343 ,  C12N2710/10351

摘要： The present invention provides a method and a composition for preserving a virus. The virus is placed in a liquid carrier with a stabilizing agent selected from the group consisting of polysorbate 80, L-arginine, polyvinylpyrrolidone, trehalose, and combinations thereof. The liquid composition can be maintained at a temperature above 0 °C for a significant period of time while maintaining a satisfactory degree of viral activity.

公开(公告)号：EP0920514B1

公开(公告)日：2008-01-02

申请号：EP97938497.1

申请日：1997-08-21

申请人： GENVEC, INC.

发明人： WICKHAM, Thomas, J. ,  ROELVINK, Petrus, W. ,  KOVESDI, Imre

IPC分类号： C12N15/34 ,  C12N15/86 ,  C07K14/075 ,  A61K48/00

CPC分类号： C12N7/00 ,  A61K38/00 ,  A61K48/00 ,  C07K14/005 ,  C07K2319/00 ,  C12N15/86 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2810/40 ,  C12N2810/405 ,  C12N2810/60

摘要： The present invention provides a chimeric adenovirus fiber protein, which differs from the wild-type coat protein by the introduction of a nonnative amino acid sequence in a conformationally-restrained manner. Such a chimeric adenovirus fiber protein according to the invention is able to direct entry into cells of a vector comprising the chimeric fiber protein that is more efficient than entry into cells of a vector that is identical except for comprising a wild-type adenovirus fiber protein rather than the chimeric adenovirus fiber protein. The nonnative amino acid sequences encode a peptide motif that comprises an epitope for an antibody, or a ligand for a cell surface receptor, that can be employed in cell targeting. The present invention also pertains to vectors comprising such a chimeric adenovirus fiber protein, and to methods of using such vectors.

公开(公告)号：EP1784416A2

公开(公告)日：2007-05-16

申请号：EP05791578.7

申请日：2005-07-15

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  GENVEC, INC.

发明人： NABEL, Gary, J. ,  HUANG, Yue ,  XU, Ling ,  CHAKRABARTI, Bimal ,  Wu, Lan ,  YANG, Zhi-yong ,  GALL, Jason, G., D. ,  King, C., Richter

IPC分类号： C07K14/16 ,  A61K39/21 ,  A61P31/00

CPC分类号： A61K39/21 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/70 ,  C07K14/005 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2740/16322 ,  C12N2740/16334 ,  C12N2740/16371

摘要： The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.

公开(公告)号：EP1740218A1

公开(公告)日：2007-01-10

申请号：EP05725429.4

申请日：2005-03-11

申请人： GENVEC, INC.

发明人： WEI, Lisa ,  RASMUSSEN, Henrik, S.

IPC分类号： A61K48/00 ,  C12N15/861 ,  A61P27/02

CPC分类号： C12N15/86 ,  A61K9/0051 ,  A61K38/1709 ,  A61K38/57 ,  A61K48/00 ,  A61K48/005 ,  C12N2710/10343

摘要： The invention is directed to a method of prophylactically or therapeutically treating an animal for vascular leakage in an eye. The method comprises administering to an animal in need thereof an expression vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) such that vascular leakage in the eye of the animal is treated prophylactically or therapeutically. The invention also provides a method of prophylactically or therapeutically treating an animal for vascular leakage in an eye. The method comprises periocularly administering to an animal in need thereof PEDF such that vascular leakage of the animal is treated prophylactically or therapeutically. The invention also provides a method of prophylactically or therapeutically treating an animal for non-diabetic vascular leakage in an eye. The method comprises administering to an animal in need thereof PEDF such that non-diabetic vascular leakage in the eye is treated prophylactically or therapeutically.

公开(公告)号：EP0778889B1

公开(公告)日：2006-07-05

申请号：EP95928312.8

申请日：1995-08-07

申请人： GENVEC, INC.

发明人： WICKHAM, Thomas J. ,  KOVESDI, Imre ,  BROUGH, Douglas E. ,  McVEY, Duncan L. ,  BRUDER, Joseph T.

IPC分类号： C12N7/01 ,  C12N15/86

CPC分类号： C12N15/87 ,  A61K48/00 ,  C07K14/005 ,  C07K14/70546 ,  C07K2319/00 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2710/14043 ,  C12N2710/14143 ,  C12N2810/40 ,  C12N2810/405 ,  C12N2810/60 ,  C12N2810/6018 ,  C12N2810/80 ,  C12N2810/855 ,  C12N2810/856 ,  C12N2810/859

摘要： A recombinant adenovirus comprising a chimeric penton base protein, which includes a nonpenton base sequence, and a therapeutic gene, a method of gene therapy involving the use of such adenovirus, and adenoviral transfer vectors for the generation of such recombinant adenovirus are provided.

公开(公告)号：EP1597377A2

公开(公告)日：2005-11-23

申请号：EP04712409.4

申请日：2004-02-18

申请人： GenVec, Inc. ,  FUSO PHARMACEUTICAL INDUSTRIES LTD.

发明人： WICKHAM, Thomas, J. ,  AKIYAMA, Masaki

IPC分类号： C12N15/861 ,  C12N15/86 ,  A61K48/00

CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2810/405 ,  C12N2810/50

摘要： The invention provides a method of expressing an exogenous nucleic acid in a mammal. The method comprises slowly releasing into the bloodstream a dose of replication-deficient or conditionally-replicating adenoviral vector having reduced ability to transduce mesothelial cells and hepatocytes. The normalized average bloodstream concentration of the adenovirus over 24 hours post-administration is at least about 1%. Alternatively, the normalized average bloodstream concentration over 24 hours post-administration is at least about 5-fold greater than the normalized average bloodstream concentration for an equivalent dose of a wild-type adenoviral vector. A method of destroying tumor cells in a mammal also is provided.